EXACT Sciences Corporation | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (48)

Latest Posts

About This Stock More About This Stock
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
Article By: Rod Raynovich
Sunday, February 5, 2023 8:10 PM EDT
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
In this article: NTLA, IBB, PACB, XBI, SUPN, CRSP, ARKG, VCYT Also: CYRX, GERN, QDEL, HOLX, VRTX, EXAS, EVH, NVTA, TDOC
Read
Five Best And Worst Performing Healthcare Stocks In January 2023
Article By: ValueWalk
Sunday, February 5, 2023 1:40 PM EDT
After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and worst performing healthcare stocks in January 2023.
In this article: BAX, CNC, PFE, ALGN, IDXX, NBIX, EXAS, ABBV, BGNE, GEHC
Read
The Stocks Behind 2022's Popular ETFs
Podcast By: Tracey Ryniec
Thursday, January 12, 2023 2:10 AM EDT
One of the most popular actively managed ETFs in 2022 for inflows was the JPMorgan Equity Premium Income ETF (JEPI). It holds 125 stocks and is currently paying a 12-month yield of 9.64%.
In this podcast: XOM, TSLA, EXAS, ABBV, ARKK, ZM, JEPI
Listen
How Do Biotechnology Funds And ETFs Perform Over Five Years?
Article By: Rod Raynovich
Monday, March 21, 2022 4:00 PM EDT
Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV.
In this article: FBIOX, PRHSX, IBB, REGN, PACB, FBT, SPY, XBI, XLV, EXAS
Read
ARKK Stocks Breakdowns And Bounces
Article By: Bespoke Investment Group
Friday, May 7, 2021 2:48 PM EDT
After struggling for most of the past couple of months, momentum and Tech stocks are broadly outperforming today.
In this article: ICE, REGN, PCAR, TRMB, COIN, EXAS, ARKK, NVTA, TDOC, CRSP, IOVA
Read

Latest Tweets for $EXAS

No tweets yet!

PARTNER HEADLINES

$EXAS

Exact Sciences: Poised For Further Growth
James Dean Samuels 11/22/2018 6:59:36 PM

Great article! Analyst consensus = strong buy with $90 price target. $PFE $EXAS

Exact Sciences: Poised For Further Growth
Beating Buffett 11/9/2018 4:28:18 AM

Article is a good summary and is likely representative of the future for $EXAS.

1 to 2 of 2 comments